{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:05:56Z","timestamp":1784541956680,"version":"3.55.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T00:00:00Z","timestamp":1570060800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T00:00:00Z","timestamp":1570060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100005440","name":"Center for Scientific Review","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100005440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1245\/s10434-019-07867-x","type":"journal-article","created":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T17:03:37Z","timestamp":1570122217000},"page":"4238-4243","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Is Clinical Exam of the Axilla Sufficient to Select Node-Positive Patients Who Downstage After NAC for SLNB? A Comparison of the Accuracy of Clinical Exam Versus MRI"],"prefix":"10.1245","volume":"26","author":[{"given":"Tracy-Ann","family":"Moo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxine S.","family":"Jochelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily C.","family":"Zabor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Stempel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Raiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Mamtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audree B.","family":"Tadros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"El-Tamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,3]]},"reference":[{"issue":"5","key":"7867_CR1","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.amjsurg.2016.07.018","volume":"212","author":"Chehade H El Hage","year":"2016","unstructured":"El Hage Chehade H, Headon H, El Tokhy O, Heeney J, Kasem A, Mokbel K. Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients. Am J Surg. 2016;212(5):969\u2013981.","journal-title":"Am J Surg."},{"issue":"7","key":"7867_CR2","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","volume":"14","author":"T Kuehn","year":"2013","unstructured":"Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609\u2013618.","journal-title":"Lancet Oncol."},{"issue":"14","key":"7867_CR3","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455\u20131461.","journal-title":"JAMA."},{"issue":"3","key":"7867_CR4","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","volume":"33","author":"JF Boileau","year":"2015","unstructured":"Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33(3):258\u2013264.","journal-title":"J Clin Oncol."},{"key":"7867_CR5","unstructured":"Network NCC. Clinical practice guidelines oncology\u2014breast cancer (version 3.2018). 2018; \nhttps:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf\n\n. Accessed 28 Jan 2018."},{"key":"7867_CR6","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.breast.2016.11.012","volume":"31","author":"L Schwentner","year":"2017","unstructured":"Schwentner L, Helms G, Nekljudova V, et al. Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy: results from the multi-center SENTINA trial. Breast. 2017;31:202\u2013207.","journal-title":"Breast."},{"issue":"11","key":"7867_CR7","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1245\/s10434-016-5246-8","volume":"23","author":"A Mamtani","year":"2016","unstructured":"Mamtani A, Barrio AV, King TA, et al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study. Ann Surg Oncol. 2016;23(11):3467\u20133474.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"7867_CR8","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s13244-013-0219-y","volume":"4","author":"MB Lobbes","year":"2013","unstructured":"Lobbes MB, Prevos R, Smidt M, et al. The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review. Insights Imaging. 2013;4(2):163\u2013175.","journal-title":"Insights Imaging."},{"issue":"11","key":"7867_CR9","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1245\/s10434-011-1919-5","volume":"18","author":"R Croshaw","year":"2011","unstructured":"Croshaw R, Shapiro-Wright H, Svensson E, Erb K, Julian T. Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients. Ann Surg Oncol. 2011;18(11):3160\u20133163.","journal-title":"Ann Surg Oncol."},{"issue":"5","key":"7867_CR10","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1200\/JCO.2008.18.3228","volume":"27","author":"JM Classe","year":"2009","unstructured":"Classe JM, Bordes V, Campion L, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol. 2009;27(5):726\u2013732.","journal-title":"J Clin Oncol."},{"issue":"5","key":"7867_CR11","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/jnci\/djs528","volume":"105","author":"ML Marinovich","year":"2013","unstructured":"Marinovich ML, Houssami N, Macaskill P, et al. Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. J Natl Cancer Inst. 2013;105(5):321\u2013333.","journal-title":"J Natl Cancer Inst."},{"key":"7867_CR12","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ejrad.2018.09.032","volume":"108","author":"J Park","year":"2018","unstructured":"Park J, Chae EY, Cha JH, et al. Comparison of mammography, digital breast tomosynthesis, automated breast ultrasound, magnetic resonance imaging in evaluation of residual tumor after neoadjuvant chemotherapy. Eur J Radiol. 2018;108:261\u2013268.","journal-title":"Eur J Radiol."},{"issue":"9","key":"7867_CR13","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1245\/s10434-014-4357-3","volume":"22","author":"MC Lee","year":"2015","unstructured":"Lee MC, Gonzalez SJ, Lin H, et al. Prospective trial of breast MRI versus 2D and 3D ultrasound for evaluation of response to neoadjuvant chemotherapy. Ann Surg Oncol. 2015;22(9):2888\u20132894.","journal-title":"Ann Surg Oncol."},{"issue":"6","key":"7867_CR14","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.jamcollsurg.2017.08.027","volume":"225","author":"JJ Weber","year":"2017","unstructured":"Weber JJ, Jochelson MS, Eaton A, et al. MRI and prediction of pathologic complete response in the breast and axilla after neoadjuvant chemotherapy for breast cancer. J Am Coll Surg. 2017;225(6):740\u2013746.","journal-title":"J Am Coll Surg."},{"issue":"6","key":"7867_CR15","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.2214\/AJR.17.18323","volume":"210","author":"JR Scheel","year":"2018","unstructured":"Scheel JR, Kim E, Partridge SC, et al. MRI, Clinical examination, and mammography for preoperative assessment of residual disease and pathologic complete response after neoadjuvant chemotherapy for breast cancer: ACRIN 6657 Trial. AJR Am J Roentgenol. 2018;210(6):1376\u20131385.","journal-title":"AJR Am J Roentgenol."},{"issue":"1","key":"7867_CR16","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jss.2016.04.048","volume":"204","author":"J Steiman","year":"2016","unstructured":"Steiman J, Soran A, McAuliffe P, et al. Predictive value of axillary nodal imaging by magnetic resonance imaging based on breast cancer subtype after neoadjuvant chemotherapy. J Surg Res. 2016;204(1):237\u2013241.","journal-title":"J Surg Res."},{"issue":"10","key":"7867_CR17","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1245\/s10434-013-3118-z","volume":"20","author":"TJ Hieken","year":"2013","unstructured":"Hieken TJ, Boughey JC, Jones KN, Shah SS, Glazebrook KN. Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer. Ann Surg Oncol. 2013;20(10):3199\u20133204.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"7867_CR18","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.clbc.2016.11.004","volume":"17","author":"AE Mattingly","year":"2017","unstructured":"Mattingly AE, Mooney B, Lin HY, et al. Magnetic resonance imaging for axillary breast cancer metastasis in the neoadjuvant setting: a prospective study. Clin Breast Cancer. 2017;17(3):180\u2013187.","journal-title":"Clin Breast Cancer."},{"issue":"7","key":"7867_CR19","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1245\/s10434-010-0934-2","volume":"17","author":"S Javid","year":"2010","unstructured":"Javid S, Segara D, Lotfi P, Raza S, Golshan M. Can breast MRI predict axillary lymph node metastasis in women undergoing neoadjuvant chemotherapy. Ann Surg Oncol. 2010;17(7):1841\u20131846.","journal-title":"Ann Surg Oncol."},{"issue":"11","key":"7867_CR20","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1007\/s00330-016-4235-4","volume":"26","author":"SJ Hyun","year":"2016","unstructured":"Hyun SJ, Kim EK, Moon HJ, Yoon JH, Kim MJ. Preoperative axillary lymph node evaluation in breast cancer patients by breast magnetic resonance imaging (MRI): Can breast MRI exclude advanced nodal disease? Eur Radiol. 2016;26(11):3865\u20133873","journal-title":"Eur Radiol"},{"issue":"30","key":"7867_CR21","doi-asserted-by":"publisher","first-page":"3386","DOI":"10.1200\/JCO.2014.57.8401","volume":"33","author":"JC Boughey","year":"2015","unstructured":"Boughey JC, Ballman KV, Hunt KK, et al. Axillary ultrasound after neoadjuvant chemotherapy and its impact on sentinel lymph node surgery: results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance). J Clin Oncol. 2015;33(30):3386\u20133393.","journal-title":"J Clin Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-07867-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-019-07867-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-07867-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T23:17:35Z","timestamp":1601594255000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-019-07867-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,3]]},"references-count":21,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["7867"],"URL":"https:\/\/doi.org\/10.1245\/s10434-019-07867-x","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,3]]},"assertion":[{"value":"22 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Monica Morrow has received speaking honoraria from Genomic Health and Roche. Dr. Mahmoud El-Tamer received honoraria from Blue Earth Diagnostic in 2016. All other authors have no conflict of interest disclosures to report.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}